Stocktoria
RxSight, Inc. RXST
Nasdaq · stock · Ophthalmic Goods · website · IPO 2021-07-30
RxSight, Inc. financials (annual)
Bars are annual figures from 2020 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | $134.5M | $139.9M | $89.1M | $49.0M | $22.6M | $14.7M |
| Gross profit | $103.0M | $98.9M | $53.8M | $21.3M | $4.5M | $1.7M |
| R&D expense | $38.5M | $34.4M | $29.1M | $26.0M | $24.5M | $21.9M |
| SG&A expense | $112.7M | $101.4M | $74.8M | $58.7M | $32.8M | $15.2M |
| Operating income | -$48.2M | -$36.9M | -$50.1M | -$63.3M | -$52.8M | -$35.4M |
| Interest expense | $19,000 | $21,000 | $3.3M | $4.9M | $3.7M | $510,000 |
| Income tax | $66,000 | $50,000 | $20,000 | $9,000 | $8,000 | $57,000 |
| Net income | -$38.9M | -$27.5M | -$48.6M | -$66.8M | -$48.7M | $27.6M |
| EPS (diluted) | $-0.95 | $-0.71 | $-1.41 | $-2.41 | $-3.57 | $0.15 |
| Operating cash flow | -$15.5M | -$16.9M | -$41.6M | -$58.9M | -$44.7M | -$35.2M |
| Free cash flow | -$19.3M | -$22.4M | -$46.4M | -$61.2M | -$46.6M | -$37.7M |
| Cash & equivalents | $19.9M | $16.7M | $9.7M | $11.8M | $24.4M | $14.0M |
| Inventory | $31.6M | $22.0M | $17.4M | $14.8M | $8.0M | $8.3M |
| Total assets | $311.8M | $318.6M | $182.6M | $150.2M | $192.7M | $100.7M |
| Total liabilities | $36.1M | $37.3M | $22.2M | $60.3M | $54.5M | $44.9M |
| Shareholders' equity | $275.7M | $281.2M | $160.4M | $89.9M | $138.2M | -$430.6M |
Growth · year-over-year · Revenue CAGR 55.7%
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue growth | -3.9% | +57.1% | +81.8% | +116.9% | +53.9% | — |
| Net income growth | — | — | — | — | -276.6% | — |
| EPS growth | — | — | — | — | -2480.0% | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.